EML4-ALK fusion gene in patients with lung carcinoma: Biology, diagnostics and targeted therapy;EML4-ALK fúzní gen u pacientů s plicním karcinomem: Biologie, diagnostika a cílená terapie

Klinicka Onkologie

Volumn 25, Issue 6, 2012, Pages 434-439

  Vašíková, Alžběta ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Crizotinib; EML4 ALK fusion protein; Molecular diagnostics; Molecular targeted therapy; Non small cell lung cancer; Protein kinase inhibitors

Indexed keywords

CRIZOTINIB;

ALK TUMOR GENE; CANCER DIAGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOME 2; EML4 ALK FUSION GENE; EML4 TUMOR GENE; FUSION GENE; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; KIF5B TUMOR GENE; KLC1 TUMOR GENE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PARACENTRIC CHROMOSOME INVERSION; PERSONALIZED MEDICINE; REVIEW; TGF TUMOR GENE; TREATMENT RESPONSE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PYRAZOLES; PYRIDINES;

EID: 84872444472     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Heneberg P. Zpřesněme indikaci podává ní inhibitorů kinázové aktivity EGFR. Klin Onkol 2010; 24(2): 87-93.
2. Skřičková J, Babičková L, Tomíšková M et al. Biologická léčba nemalobuněčného karcinomu plic. Interní Med 2011; 13(7,8): 292-295.
3. Zatloukal P. Biologická léčba nemalobuně čného karcinomu plic. Onkologie 2009; 3(5): 292-296.
4. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004; 304(5676): 1497-1500.
5. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-957.
6. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29(21): 2866-2874.
7. Zemanová M. Gefitinib v monoterapii u nemocných s pokročilým NSCLC nesoucím aktivující mutaci EGFR zlepšuje významně léčebné výsledky oproti standardní chemoterapii - aktualita z klinické praxe. Klin Onkol 2010; 23(5): 365-366.
8. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2): 121-128.
9. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12(8): 735-742.
10. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13(3): 239-246.
11. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12(6): 713-718. (Pubitemid 47036205)
12. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561-566. (Pubitemid 47206930)
13. Pollmann M, Parwaresch R, Adam-Klages S et al. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 2006; 312(17): 3241-3251. (Pubitemid 44380227)
14. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expresssed specifically in the nervous system. Oncogene 1997; 14(4): 439-449. (Pubitemid 27087107)
15. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263(5151): 1281-1284. (Pubitemid 24107549)
16. Griffin CA, Hawkins AL, Dvorak C et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59(12): 2776-2780. (Pubitemid 29283106)
17. Arber DA, Sun LH, Weiss LM. Detection of the t(2;5) (p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol 1996; 27(6): 590-594. (Pubitemid 26187284)
18. Sugawara E, Togashi Y, Kuroda N et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012; 118(18): 4427-4436.
19. Lin E, Li L, Guan Y et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009, 7(9): 1466-1476.
20. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455(7215): 971-974.
21. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14(20): 6618-6624.
22. Koivunen JP, Mermal C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14(13): 4275-4283.
23. Sasaki T, Rodig SJ, Chirieac LR et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46(10): 1773-1780.
24. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68(13): 4971-4976.
25. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131(6): 1190-1203. (Pubitemid 350235027)
26. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15(9): 3143-3149.
27. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012; 7(2): e31323.
28. Soda M, Takada S, Takeuchi K et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008; 105(50): 19893-19897.
29. Perner S, Wagner PL, Demichelis F et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008; 10(3): 298-302. (Pubitemid 351328588)
30. Fukuyoshi Y, Inoue H, Kita Y et al. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 2008; 98(9): 1536-1539. (Pubitemid 351652334)
31. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3(1): 13-17.
32. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174(2): 661-670.
33. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15(16): 5216-5223.
34. Jin G, Jeon HS, Lee EB et al. EML4-ALK fusion gene in Korean non-small cell lung cancer. J Korean Med Sci 2012; 27(2): 228-230.
35. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27(26): 4247-4253.
36. Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010; 9: 188.
37. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16(22): 5581-5590.
38. Yi ES, Boland JM, Maleszewski JJ et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011; 6(3): 459-465.
39. Sanders HR, Li HR, Bruey JM et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011; 204(1): 45-52.
40. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry Clin Cancer Res 2010; 16(5): 1561-1571.
41. Li Y, Ye X, Liu J et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011; 13(1): 1-11.
42. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010; 363(18): 1693-1703.
43. Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12(21): 6494-6501. (Pubitemid 44799723)
44. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363(18): 1734-1739.
45. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108(18): 7535-7540.
46. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19(5): 679-690.